SC 13G/A: Roivant Sciences Ltd.
Ticker: ROIV · Form: SC 13G/A · Filed: Feb 14, 2024 · CIK: 1635088
Sentiment: neutral
Topics: sc-13g-a
AI Summary
SC 13G/A filing by Roivant Sciences Ltd..
Risk Assessment
Risk Level: low
Filing Stats: 1,050 words · 4 min read · ~4 pages · Grade level 9.4 · Accepted 2024-02-14 06:51:31
Key Financial Figures
- $0.0000000341740141 — me of Issuer) Common shares, par value $0.0000000341740141 per share (Title of Class of Securiti
Filing Documents
- tm246088d1_sc13ga.htm (SC 13G/A) — 67KB
- 0001104659-24-022840.txt ( ) — 68KB
(a)
Item 1(a). Name of Issuer. The name of the issuer is Roivant Sciences Ltd. (the “Issuer”).
(b)
Item 1(b). Address of Issuer’s Principal Executive Offices. The Issuer’s principal executive offices are located at 7th Floor, 50 Broadway, London SW1H 0DB, United Kingdom
(a)
Item 2(a). Name of Person Filing. This Schedule 13G is filed on behalf of Dexcel Pharma Technologies Ltd. (“DPT”), Dexxon Holdings Ltd.(“Dexxon”) and Dan Oren (each a “Reporting Person” and together, the “Reporting Persons”).
(b)
Item 2(b). Address of Principal Business Office or, if none, Residence. The principal business address of DPT is 10 Hakidma Street, Yokneam Illit 2069200, Israel. The principal business address of Dexxon and Dan Oren is 1 Dexcel Street, Or Akiva, 3060000, Israel.
(c)
Item 2(c). Citizenship. DPT and Dexxon are incorporated under the laws of Israel. Dan Oren is an Israeli citizen.
(d)
Item 2(d). Title of Class of Securities. Common shares, par value $0.0000000341740141 per share.
(e)
Item 2(e). CUSIP No. G76279101 Item 3. Not applicable. Item 4. The information required by Items 4(a)-(c) is set forth in Rows (5)-(11) of the cover page for each Reporting Person. Dan Oren is the Executive Chairman of DPT and a director of Dexxon and is ultimately the controlling shareholder of each of DPT and Dexxon. Accordingly, Dan Oren may be deemed to have investment control over the Common Shares owned directly by DPT and Dexxon. Item 5. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities check the following: Item 6. Not applicable. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person. Not applicable. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certification. Not applicable. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. DATE: February 14, 2024 /s/ Dan Oren Dan Oren DEXCEL PHARMA TECHNOLOGIES LTD. By: /s/ Dan Oren Name: Dan Oren Title: Executive Chairman DEXXON HOLDINGS LTD. By: /s/ Dan Oren Name: Dan Oren Title: Director